期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 12, 期 10, 页码 1275-1287出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.10.1275
关键词
Alzheimer's disease; cancer; cancer metastasis; GPCR; MAPK; NF-kappa B; PEBP; RKIP
资金
- National Institutes of Health [NS33858, CA112310]
- University of Chicago Cancer Research Center
- Cornelius Crane Trust for Eczema Research
- NATIONAL CANCER INSTITUTE [R01CA112310] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033858] Funding Source: NIH RePORTER
Background: Raf kinase inhibitory protein (RKIP) belongs to the phosphaticlylethanolamine binding protein (PEBP) family that is expressed in both prokaryotic and euakaryotic organisms. Objective: In this review, we discuss the role of RKIP as a modulator of signal transduction, the relationship of RKIP to other members of the PEBP family, and the role of RKIP in human health and disease. Results/conclusion: In mammals, RKIP regulates activation of MAPK, NF-kappa B and G protein coupled receptors (GPCRs). As a modulator of key signaling pathways, RKIP affects various cellular processes including cell differentiation, the cell cycle, apoptosis and cell migration. Emerging evidence suggests that RKIP is implicated in several human diseases or disorders, among them metastatic tumorigenesis and Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据